Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month

New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the most common cancer in American men other than skin cancer according to the American Cancer Society, along with bladder, testicular and kidney cancers are all diseases of the urinary tract and male reproductive tract. When men have the information and resources they need, they may feel more empowered to take control of their urologic and overall health. 

Experts in the Urologic Oncology Program at Rutgers Cancer Institute of New Jersey have specialized clinical and research interest in tumors of the prostate, testis, kidney, and bladder. Members in our group of urologic oncologists, medical oncologists and clinicians, who work to provide comprehensive cancer care in collaboration with the oncology service line of RWJBarnabas Health, are available for comment during men’s health month:

Thomas L. Jang, MD, MPH, is associate chief of Urologic Oncology and a urologic oncologist at Rutgers Cancer Institute and associate professor of surgery at Rutgers Robert Wood Johnson Medical School. Dr. Jang has extensive experience in the care and treatment of patients diagnosed with any cancer involving the urinary or genital tract, particularly those with high-risk cancers requiring complex treatment. His expertise includes surgery for patients with advanced stage kidney cancer, complex partial kidney surgeries and managing patients with prostate and bladder cancers.

Eric Singer, MD, MA, FACS, is associate chief of Urology and director of the Kidney Cancer Program a Rutgers Cancer Institute and associate professor of surgery and radiology at Rutgers Robert Wood Johnson Medical School. Dr. Singer has expertise in the management of genitourinary malignancies and a special interest in using robotic and minimally invasive surgery to treat cancers of the kidney, prostate, bladder and adrenal glands. Dr. Singer’s goal is to educate and empower his patients so that they can choose the best treatment option available, whether it is surgery, active surveillance, radiation, systemic therapy or a clinical trial.  

Saum Ghodoussipour, MD, is director of the Bladder and Urothelial Cancer Program and a urologic oncologist at Rutgers Cancer Institute and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School.  Dr. Ghodoussipour’s clinical areas of expertise include complex open and robotic surgeries of the pelvis and retroperitoneum. He has recently treated Rutgers Cancer Institute’s first upper tract urothelial cancer (UTUC) patient with a new therapy called mitomycin gel, which is the first non-surgical therapy option for this type of cancer.

Biren Saraiya, MD, is a medical oncologist in the Urologic Oncology Program at Rutgers Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. Dr. Saraiya’s clinical expertise includes prostate cancer, kidney cancer, testicular cancer, bladder cancer and palliative care. He works closely with basic research scientists and clinical researchers at Rutgers Cancer Institute to develop new therapies for genitourinary cancers. 

Tina Mayer, MD, is a medical oncologist in the Urologic Oncology Program at Rutgers Cancer Institute and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School. Dr. Mayer’s expertise includes prostate cancer, kidney cancer, bladder cancer, testis cancer, and penile cancer. Within these areas of specialty, she provides patients with a comprehensive evaluation and helps educate them about their disease so that they can make informed decisions about their treatment options. She is also involved in conducting clinical trials within areas of her specialty.

                          ###